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Human Topoisomerase II Alpha Nuclear Export Is Mediated by
Two Crm-1 Dependent Nuclear Export Signals

Joel G. Turner

ABSTRACT

Resistance to chemotherapeutic drugs is a major obstacle in the treatment of
leukemia and multiple myeloma. We have previously found that myeloma and leukemic
cells in transition from low-density log phase conditions to high-density plateau phase
conditions exhibit a substantial export of endogenous topoisomerase II alpha from the
nucleus to the cytoplasm. In order for topoisomerase-targeted chemotherapy to function,
the topoisomerase target must have access to the nuclear DNA. Therefore, the nuclear
export of topoisomerase II alpha may contribute to drug resistance, and defining this
mechanism may lead to methods to preclude this avenue of resistance. In the current
report, we have defined nuclear export signals for topoisomerase II alpha at amino acids
1017-1028 and 1054-1066, using FITC labeled BSA-export signal peptide conjugates
microinjected into the nuclei of HeLa cells. Functional confirmation of both signals
(1017-1028 and 1054-1066) was provided by transfection of human myeloma cells with
plasmids containing the gene for a full-length human FLAG-topoisomerase fusion
protein, mutated at hydrophobic amino acid residues in the export signals. Of the six
putative export signals tested, the two sites above were found to induce export into the
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cytoplasm. Export by both signals was blocked by treatment of the cells with leptomycin
B, indicating that a CRM-1 dependent pathway mediates export. Site-directed
mutagenesis of two central hydrophobic residues in either export signal in full-length
human topoisomerase blocked export of recombinant FLAG-topoisomerase II alpha,
indicating that both signals may be required for export. Interestingly, this pair of nuclear
export signals (1017-1028 and 1054-1066) also defines a dimerization domain of the
topoisomerase II alpha molecule.
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INTRODUCTION
Topoisomerase II alpha Structure and Function
The fundamental problem with developing therapies against cancer is that cancer
cells are extremely similar to normal cells both immunologically and physiologically.
This similarity makes it difficult to design therapies that can selectively destroy the
cancer without collateral damage to healthy cells. One strategy to accomplish this is to
selectively target rapidly dividing cells. This selective targeting is the basic principle
involved when using topoisomerases as targets for cancer chemotherapy. Topoisomerases
are highly expressed in proliferating cells and are absolutely essential for cell survival.
Without topoisomerases, replication of DNA, transcription of RNA and chromatin
assembly would be impossible.
It is appropriate to first briefly explain the normal structure and function of
topoisomerase IIα in cells in order to address how various agents inhibit topoisomerase
IIα and induce cell death (Bakshi, et al., 2001). The primary function of topoisomerase
IIα is to catalyze the breaking and rejoining of double-stranded DNA in order to relax
supercoiled structures, and resolve nucleic acid knots and tangles. Topoisomerase IIα is
composed of three domains; an amino-terminal ATPase domain, a central catalytic
domain which includes an active tyrosine site, and a carboxy-terminus domain which
contains the nuclear localization signal (NLS) and other potential phosphorylation sites
(Figure 1).
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Two topoisomerase molecules form a homodimer that creates a transient break
(gate) in a duplex DNA, transports a second strand through the gate, and then religates
the cleaved strand (Liu, et al., 1980). To provide a stable structure during
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Figure 1: Domain map of human topoisomerase II alpha

transport of the second strand, the active site tyrosines of topoisomerase form a covalent
bond with the 5' termini of the DNA gate.
Topoisomerase IIα has the ability to recognize and bind to topological structures
such as negative and positive supercoiled nucleic acids. After binding to the DNA, and in
the presence of a divalent cation, the enzyme forms double-stranded nicks on opposite
strands of the double helix leaving a four base 5' overhang on each cleaved strand (Lui, et
al., 1983). Formation of covalent linkages does not require ATP because the enzymecleaved DNA complex conserves the chemical energy of the phosphodiester bond
(transesterification). However, ATP binds as a co-factor and triggers a conformational
change that allows strand passage through the gate. After strand passage and ligation of
the DNA break, ATP hydrolysis is required for the opening of the molecule to release the
nucleic acid products.
2

Therapeutic Agents That Target Topoisomerase II alpha
Drugs that target topoisomerase IIα consist of two types, topoisomerase poisons,
and catalytic inhibitors (Andoh and Ishida, 1998). Topoisomerase poisons cause the
enzyme itself to produce great numbers of double-stranded breaks in the DNA, whereas
catalytic inhibitors act as antagonists, which inhibit enzyme activity. There are currently
six anti-neoplastic drugs the FDA has approved for clinical use that act on topoisomerase
IIα; etoposide, teniposide, doxorubicin, daunorubicin, idarubicin, and mitoxantrone
(Burden and Osheroff, 1998). All drugs presently in clinical (non-investigational) use are
topoisomerase poisons.

Etoposide and Topoisomerase II alpha
Remarkably, etoposide containing plant derivatives have been used for centuries
to treat skin cancers in India (Slevin, 1991). Etoposide was first isolated in 1966, received
FDA approval for treatment of cancer in 1983, but it wasn’t until 1984 that a connection
between etoposide and topoisomerase IIα inhibition was made. Etoposide does not block
topoisomerase catalytic functioning; instead, it increases the concentration of DNA
cleavage complexes in proliferating cells. Etoposide specifically binds to topoisomerase
IIα. Etoposide binding prevents strand passage and traps the enzyme in a conformation
possessing a double stranded DNA break with the active tyrosine groups covalent-linked
to each separated strand. When replicating machinery or helicases attempt to traverse this
topoisomerase roadblock, permanent double-stranded breaks in the DNA are made. The
DNA breaks become involved in recombination events generating large deletions and
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insertions resulting in genomic instability in dividing cells, and eventually lead to cell
death by apoptosis (Hande, 1998).

Etoposide Mechanism of Inhibition
Etoposide has a relatively weak affinity for DNA and functions by preventing the
DNA religation step of topoisomerases IIα by directly binding the enzyme. Although
etoposide has been used to treat cancer for many years, it is still unclear as to how it
binds its target enzyme. A recent study has given a strong indication how etoposide
works as a topoisomerase poison (Leroy, et al., 2001).
Etoposide binding was examined in the absence of DNA using radiolabeled
etoposide and recombinant proteins from the N-terminal ATPase (aa 1-266) and catalytic
(aa 430-1214) domains of topoisomerase IIα. Affinities (Kd values) of etoposide
for the ATPase and catalytic subunits of human topoisomerase IIα were found to be 20
and 9µM respectively. ATP was found to displace etoposide from the N-terminal domain
and full-length topoisomerase, but not from the catalytic core domain. In addition, a
computer generated molecular model of the N-terminal domain of topoisomerase IIα was
produced and molecular docking analysis of etoposide was performed. Using the
molecular models, amino acids that were predicted to come in contact with etoposide
were mutated. The mutated N-terminal domain proteins had significantly reduced drug
binding efficiencies, which strongly suggests that etoposide can interact with the ATP
binding pocket of eukaryotic topoisomerase IIα in vitro. Two possible models would be
consistent with these results, either the N-terminus and catalytic sites cooperate to form a

4

single binding unit or the sites bind in a separate manner and compete for the drug
(Leroy, et al., 2001).
Etoposide and Drug Resistance
Cancer chemotherapy with anti-topoisomerase II drugs can lose its effectiveness
when cells develop resistance to the action of the drug. Drug resistance in cancer patients
to etoposide can be produced in multiple ways. Upregulated expression of p-glycoprotein
and breast cancer resistance protein has been found in some drug resistant human cell
lines (Litman, et al., 2001). These cell lines are normally derived from cancer patients
and selected in vitro for drug resistance with chronic levels of drug. Breast cancer
resistance protein and p-glycoprotein are essentially molecular pumps that increase the
rate of drug efflux from the cells and thereby confer resistance.
An atypical means of drug resistance is the development of mutant
topoisomerases in cancer cells (Okada, 2001), (Mao, et al., 1999). Interestingly, the
particular mutations which confer resistance are found in the ATPase domain and in the
catalytic domain of topoisomerase, sites very similar to those predicted for etoposide
binding. These mutations also decrease the catalytic efficiency of topoisomerase IIα.
Additional mutated topoisomerases have been reported in the carboxy terminus region of
topoisomerase IIα (Yu, et al., 1997). This type of mutation produces a cytoplasmic form
of topoisomerase IIα because the nuclear localization signal (NLS) has been truncated
(Figure 1). For topoisomerase IIα to cause lethal breaks in the DNA it must be in the
nucleus, therefore cells expressing a cytoplasmic variety would not be affected by
etoposide. It has been speculated that the cytoplasmic topoisomerase IIα provides a
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cytoplasmic buffer or sink that will bind up etoposide before it can reach the nucleus, and
subsequently result in drug resistance (Yu, et al., 1997).

Rational Drug Design Based On Etoposide Molecular Structure
Most chemotherapeutic agents originate from natural biological sources such as
plants and bacteria. This type of drug development is very difficult, labor intensive, and,
at best, is a hit-or-miss proposition. A more logical methodology would be to alter the
molecular structures of drugs already known to be effective. Molecular alterations could
be designed to improve drug action, counter drug resistance, increase uptake, or reduce
toxicity. In order to enhance the cytotoxic effect of etoposide to topoisomerase IIα, a
glycoside moiety of etoposide was substituted by an aminoalkyl group to produce a new
drug, TOP-53 (Byl, et al., 2001).
Compared to etoposide, TOP-53 was more effective in killing cancer cells, generated
more chromosomal breaks, and had improved cellular uptake in animal studies. The in
vitro effective dose was seven fold lower than that of the parent drug. TOP-53 was also
found to be effective against mutant topoisomerases that were resistant to etoposide.
Early TOP-53 experimental results clearly demonstrate the important role of the
particular modified side group in mediating drug-enzyme interactions. This opens the
door for additional potential modifications of the same side group.
Etoposide has an additional problem in that it is relatively insoluble in water. Very
large fluid volumes are required to administer the drug to patients. To address this
problem, an etoposide methyl side group was replaced by a phosphate moiety (Hande,
1998). The new drug, etoposide phosphate, was found to be more easily administered to
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patients, had less toxic side effects, and increased uptake, while maintaining the clinical
effectiveness of etoposide.

Nuclear Import and Export: Overview
In nuclear-cytoplasmic trafficking, there are three key components: 1) the nuclear
pore complex, 2) transport receptor molecules and related components, and 3) the protein
or RNA cargo itself. All nucleocytoplasmic trafficking events proceed through the
nuclear pore complex (NPC). The NPC is one of the largest macromolecular assemblies
in the eukaryotic cell, which serves as a portal in the double membrane of the nuclear
envelope. Recent investigations have elucidated several molecular pathways for the
nuclear import and export of proteins (Kau and Silver, 2003; Weis, 2003) across transport
passageways or nuclear pore complexes (NPC) (Dreger, 2003). The NPC is a large (125
MDa) multimeric protein structure that perforates the nuclear envelope and channels
proteins greater than 60 kDa into or out of the nucleus. The constituents of the NPC have
been described in yeast (Rout, et al., 2000) and mammalian cells (Cronshaw, et al.,
2002). Nuclear export/import receptor proteins, which are specifically bound to cargo
proteins, interact with FG-nucleoporins (F-phenylalanine, G-glycine) on the NPC. FGnucleoporins line the NPC channel and are thought to act as "step-stepping stones" as the
receptor complex binds to successive FG-repeats and thereby makes its way through the
NPC channel. The nucleoporins form a hydrophobic mesh that is thought to restrict
proteins that are not complexed with receptor molecules.
There are three types of transport receptors which have been identified: 1) the
importinβ-like proteins, also known as karyopherins (including Impβ, transportin, Crm1,
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and CAS), 2) the nuclear transport factor 2 (NTF2/p10) homodimer (imports GTPase Ran
into the nucleus), and 3) the Tap/Mex67 family (transports mRNA). Transport receptors
move between the nucleus and cytoplasm by interacting with nucleoporin complexes in
the NPC, specifically those that have phenylalanine/glycine (FG)-rich motifs (Weis,
2002). The protein cargo is released into the cytoplasm when Ran-GTP is hydrolyzed to
Ran-GDP by a GTPase-accelerating protein (Ran-GAP). Ran-GDP is then transported
back into the nucleus and guanine nucleotide-exchange factor then swaps out Ran-GDP
for GTP (Ribbeck, et al., 1998). In this manner, continued nuclear-cytoplasmic shuttling
occurs by maintaining a gradient of Ran-GTP in the nucleus and Ran-GDP in the
cytoplasm (Gorlich, 1998). RanGTP is formed exclusively in the nucleus because the Ran
guanine nucleotide exchange factor (RanGEF) is bound to the DNA via histone
complexes, whereas RanGDP is exclusive to the cytoplasm because the Ran GTPaseactivating protein (RanGAP) is located in the cytoplasm. Exclusive localization of
RanGAP to the cytoplasm and RanGEF to the DNA maintains a gradient even during
cellular division. Translocation through the NPC itself does not require energy and is
reversible. The concentration gradient provided by the RanGTP cycle provides the energy
input required to produce transport in importin-exportin mediated transport. The RanGTP
gradient also creates a specific directionality by regulation of the substrate binding and
release reactions.
Proteins targeted for receptor-mediated transport across the NPC must either
contain a nuclear localization signal (NLS) or a nuclear export signal (NES). Protein
NLS are typically short clusters of basic amino acids, often preceded by an acidic amino
acid or proline residue. However, a NLS may also consist of bipartite clusters of basic
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amino acids separated by a spacer region of approximately ten amino acids, often flanked
by a neutral or acidic amino acid. Previously described NLS are annotated in SWISSProt (Bairoch and Apweiler, 2000) and PIR (Wu, et al., 2002), and can be retrieved at the
NLS database located at the Predict NLS server (Cokol, et al., 2000). Protein NES are
hydrophobic rich sequences that have a characteristic spacing of leucine, isoleucine,
valine, and/or phenylalanine. To date, approximately 75 experimentally validated
protein-NES have been identified and compiled in the NESbase version 1.0 database (La
Cour, et al., 2000). In general, protein import occurs when the transport receptors,
importin-α and importin-β, form a complex with the protein-NLS and escort the protein
cargo across the NPC into the nucleus (Yoneda, et al., 1999). The protein cargo is
released into the nucleus when importin-α binds Ran-GTP. Protein export occurs when
Ran-GTP and the nuclear export receptor, CRM-1, binds to a protein bearing an NES and
transports the protein cargo into the cytosol (Fukuda, et al., 1997; Fornerod, et al., 1997;
Ossareh, et al., 1997).
Topoisomerase IIα is targeted to the nucleus via a bipartite NLS located in the
carboxyl-terminus, whereas topoisomerase IIβ contains two NLS comparable to the
region in topoisomerase IIα and a third weaker NLS (Cowell, et al., 1998; Mirski, et al.,
1999).

Cellular Requirements for Crm1 Mediated Export
Using a recombinant and fluorescently conjugated Crm1 protein which was
microinjected into cells, it was found that Crm1 import is not temperature-dependant
(Zhang, et al., 2003). More importantly, Crm1 import into the cell nucleus does not
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require ATP, Ran, or Ran-dependent GTP hydrolysis. Nuclear import of Crm1 is not by
passive diffusion, but via an active translocation process that is blocked by NPC binding
by wheat germ agglutinin. Crm1 nuclear import is blocked by an excess of importinβ,
implying that the two molecules compete with one another and, therefore, possibly
interact with the same target site on the NPC. However, export of Crm1 is stopped by
ATP depletion in vivo. The ATP requirement is not indirectly related to production of
GTP because export did not occur in the presence of RanGTP without the addition of
ATP also (Zhang, et al., 2003). Restoration of Crm1 export by the addition of ATP
suggests that an ATP-consuming step is needed for Crm1 nuclear export.

Cancer and Disregulation of Nuclear Export
In order for a neoplasm to develop, many changes must take place genetically
and/or epigenetically. The hallmarks of cancer include, uncontrolled proliferation,
insensitivity to negative growth regulation, evasion of apoptosis, lack of senescence,
invasion and metastasis, angiogenesis, and genomic elasticity (Hanahan and Weinberg,
2000). Many of the genes and proteins that control these hallmarks are regulated by
nuclear-cytoplasmic trafficking. Nuclear localization is essential to protein function.
Transcription factors, activators or repressors must have access to genomic DNA in order
perform their respective functions.
Nuclear transport can be regulated in at least three ways; 1) modification of the
cargo, 2) the transporters, or 3) the nuclear pore complex itself. Modifications of the
cargo could be via phosphorylation, ubiquitinylation, glycosylation, sumoylation, or
methylation. Mutations or deletions of nuclear localization signals and/or nuclear export

10

peptide sequences would prevent binding by transporter proteins and subsequently
prevent nuclear-cytoplasmic shuttling. In the same manner, masking of signals by
additional proteins or by protein folding could disrupt trafficking. Some binding partners
are necessary for nuclear localization; therefore, alterations in binding partners could also
disregulate trafficking. The tumor suppressor BRCA1 must disengage from its binding
partner (BARD1) in order to be exported (Baer and Ludwig, 2002).
Mutations in the transporter proteins or other essential transporter related proteins
such as RanGTP could cause disregulation of nuclear shuttling. The nuclear pore proteins
could be altered in such a way to either limit or promote transport (export or import) of
specific proteins such as oncogenic or tumor suppressive proteins.
Most of the research done on tumor suppressor genes has been directed towards
genetic or epigenetic knockout of specific genes. However, defects in nuclear shuttling of
tumor suppressive factors, such as APC, p53, VHL, and BRCA1, can circumvent their
respective tumor suppressive effect (Fabbro and Henderson, 2000). A similar mechanism
may exist in the trafficking of topoisomerases out of the nucleus into the cytoplasm.
The proto-oncogene and transcriptional activator NF-κB is an example of
misregulation of cellular trafficking (Kau, et al., 2004). NF-κB promotes cell
proliferation, is anti-apoptotic, and is involved in resistance to anticancer therapies.
Regulation of NF-κB translocation is performed by its binding to IκB, blocking its NLS
and keeping it in the cytoplasm. NF-κB is released when IκB is phosphorylated and
subsequently degraded, exposing the NF-κB NLS and allowing nuclear import.
Acetylation of NF-κB by p300 inhibits dimerization with IκB and prevents any
subsequent nuclear export. NF-κB is almost exclusively located in the nucleus in many
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types of cancer, for example, lymphoma, leukemia, breast, ovarian, colon, pancreatic and
thyroid tumors. Defects that cause aggressive phosphorylation of IκB or hyperacetylation
of NF-κB by p300 are mechanisms that promote NF-κB nuclear localization and its
subsequent tumor promotion.
Another molecule that is regulated by nucleocytoplasmic transport is the signaling
molecule AKT. Constituent activation of AKT signaling can result in uncontrolled
cellular proliferation and tumorogenesis (Kau, et al., 2004). In normal cells AKT activity
is regulated by PTEN, which inhibits phosphorylation of AKT by phosphatidylinositol 3kinase (PI3K). In cancer cells that lack PTEN activity, AKT is activated by PI3K and
phosphorylates the tumor suppressors FOXO and p27, leading to their export from the
nucleus. FOXO and p27 must be in the nucleus to inhibit E2F activation. E2F is a
transcription factor that promotes cell-cycle progression by directing the expression of a
number of cell cycle genes include various cyclins and cyclin dependent kinases (CDK).

Drug Resistance via Nuclear Export of Topoisomerase II alpha
Protein degradation and altered subcellular localization of topoisomerase have
been postulated as two potential mechanisms that contribute to cellular drug resistance;
by attenuating the amount of drug target in the nucleus (Valkov, et al., 1997; Valkov et
al., 2000; Sullivan, et al., 1987; Kang, et al., 2002; Engel, et al., 2004). For example,
adhesion of human myelomonocytoid U937 cells to fibronectin by α1 integrin protects
cells against mitoxantrone and etoposide-mediated DNA damage, and is accompanied by
an altered sub-nuclear relocalization of topoisomerase IIβ to the nucleolus (Hazelhurst, et
al., 2001). Similar changes in cellular localization were found in multiple myeloma cells
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that adhered to endothelial cells (Figure 2). Thus, changes in the nuclear localization or
binding properties of the nuclear pool of topoisomerase IIβ protein may have a role in
cellular drug resistance to etoposide and mitoxantrone in these cells.

Figure 2: Immunofluorescent microscopy staining for topoisomerase II alpha. H929
multiple myeloma cell adhesion to endothelial cells causes translocation of topoisomerase
II to the cytoplasm. B) Non-adherent H929 cells. (Sullivan Lab, unpublished data).
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As previously reported, topoisomerase IIα resides in the cytoplasm of several
plateau-phase human hematological cell lines (8226, CCRF, H929, HL-60), and that the
cytoplasmic translocation paralleled a decrease in sensitivity to etoposide (Valkov, et al.,
2000; Engel, et al., 2004) (Figure 3)). No difference in the concentration or molecular
mass of topoisomerase I, IIα, or IIβ was observed, indicating that the cytoplasmic
location was not a result of protein degradation or of a truncated enzyme. These data may
also be clinically relevant, in that topoisomerase IIα has been found to have a
cytoplasmic distribution in malignant plasma cells from bone marrow aspirates from
patients with multiple myeloma (Valkov, et al., 2000). In summary, these data suggest
that topoisomerase IIα may be translocated from the nucleus to the cytoplasm under
specific cellular conditions, and this may result in altered drug sensitivity.
Although there is evidence that topoisomerase IIα can be transported between the
nucleus and cytoplasm (Valkov, et al., 2000; Oloumi, et al., 2000), the majority of data
are limited to describing the import of topoisomerase into the nucleus from the cytosol.
In fact, there has been only one study that has addressed the mechanism of the nuclear
export of topoisomerase (Mirski, et al., 2003). The results of this study were restricted to
predicting the existence of an NES in topoisomerase IIα and topoisomerase IIβ from
peptide studies, and did not define a functional NES in the full-length protein (Mirski, et
al., 2003). The results of this study demonstrate that human topoisomerase IIα contains
two functional LMB-sensitive NES in the full-length protein.
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Figure 3: Immunofluorescent staining for topo II (A, D, G and J), histones (B, E, H and
K) and merged images (C, F, I and L) in log and plateau phase CCRF and 8226 cell lines.
Log phase 8226 cells (A-C) were at a density of 2x105 cells/ml; plateau phase 8226 cells
(D-F) at 9x105 cells/ml; log phase CCRF cells (G-I) at 2x105 cells/ml; and plateau phase
CCRF cells (J-L) at 1.6x106 cells/ml (Valkov et al., 2000).
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MATERIALS AND METHODS
Cell Culture and Accelerated-plateau Cell Model
HeLa cells were grown in Alpha Minimal Essential Medium (Gibco) containing
0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate, 100 U/ml penicillin, 100
µg/ml streptomycin and 10% FBS (Hyclone). HL-60 leukemia cells and H929 myeloma
cells were grown in RPMI media containing 100 U/ml penicillin, 100 µg/ml streptomycin
and 10% FBS (Hyclone). The nuclear-cytoplasmic trafficking of topoisomerase IIα was
examined by plating cells in an accelerated-plateau cell model previously described in
this laboratory (Valkov, et al., 2000; Engel, et al., 2004). For HL-60 and H929 cells, logphase conditions are defined by growing cells at 2.0 x 105 cells/ml and plateau-phase cells
at 2.0 x 106 cells/ml. Both log and plateau phase cells were grown in fresh media in a 5%
CO2 incubator at 37°C for 24 hours prior to experiments.

Putative NES Peptides
The complete amino acid sequence for human topoisomerase IIα (accession number
NP 001058) was downloaded from the National Center for Biotechnology Information
database and searched for matches to the NES consensus sequence from Table I. Six amino
acid sequences in topoisomerase IIα matched the NES consensus sequence (Table II), and
were synthesized as native (nt) or mutated (∆) peptides. The mutated peptides contain alanine
in place of those hydrophobic residues suspected of being critical for nuclear export (leucine,
isoleucine, or valine). To facilitate conjugation with preactivated SMCC-BSA, the NES-
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peptides were designed with a cysteine residue at the amino terminus. The peptides obtained
from the Biopeptide Company (San Diego, California) were as follows: (NES80-91),
C80GLYKIFDEILVN91; (mutated NES80-91), C∆80GAYKAFDEAAAN91; (NES230-241),
C230SLDKDIVALMVR241; (mutated NES230-241), C∆230SADKDAAAAMAR241; (NES467-476),
C467TLAVSGLGVVG477; (mutated NES467-477), C∆467TAAASGAGAAG477; (NES1017-1028),
C1017DILRDFFELRLK1028; (mutated NES1017-1028), C∆1017CDIARDAFEARAK1028. Peptides
(NES569-580), C569FLEEFITPIVKV580; (mutated NES569-580), C∆569AAEEAATPAAKA580;
(NES1054-1066), C1054FILEKIDGKIIIE1066; and (mutated NES1054-1066);
C∆1054FIAEKADGKAIAE1066 were obtained from the University of Florida Protein Chemistry
Core Facility (Gainesville, FL). All peptides were HPLC purified to >95% and analyzed by
mass spectroscopy. In addition, peptide sequences and purity were confirmed by Rick
Feldhoff, PhD, at the University of Louisville, School of Medicine, Department of
Biochemistry (Louisville, KY).

Table I. Determination of a Consensus Sequence from Established NES
α-actin (Wada, et al., 1998)
β-actin (Wada, et al., 1998)
TFIIIA (Fridell, et al., 1996)
PKIα (Wen, et al., 1995)
MAPKK (Fukuda, et al., 1996)
RevHIV-1 (Fischer, et al., 1996)
Ran BP-1 (Zolotukhin and Felber, 1997)
C-Abl (Taagepera, et al., 1998)
hZyxin (Nix and Beckerle, 1997)
MdM2 (Roth, et al., 1998)
P53 (Strommel, et al., 1999)
NES
Consensus

A
A
E
A
Q
K
L
S
F

L
L
L
L
L
L
V
L
T
L
R
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P
P
A
Q
A
E
M
S
E

H
H
P
L
K
P
E
S
K
F
L

A I M R L
A I L R L
V L E N L
K L A G L
K L E E L
P L E R L
K L E A L
N L R E L
E V E E L
D E S - L
N E A L E
HX1-4HX2-3HXH
X = Leu, Ile, Val, or Phe

D
D
T
D
E
T
S
Q
E
A
L

L
L
L
I
L
L
V
I
L
L
K

A
A
N
D
D
R
C
L
C
D

Generation of BSA-peptide-FITC Conjugates
The generation of BSA-peptide -FITC conjugates was performed by Roxane
Engel. Peptides were crosslinked to BSA and FITC as previously described (Stommel et
al., 1999). A total of 2 mg Imject® Maleimide activated sulfosuccinmidyl 4-(Nmaleimidomethyl) cyclohexane-1-carboxylate bovine serum albumin (Sulfo-SMCC
BSA) (Pierce, Rockford, IL) were reconstituted in 200 µl distilled water. Then, a molar
excess (1-2 mg) of native or mutated topoisomerase IIα NES peptide in 400 µl of
conjugation buffer (83 mM sodium phosphate buffer, 0.1 M EDTA, 0.9 M NaCl, 0.002%
sodium azide, pH 7.2) was mixed with the Sulfo-SMCC BSA and reacted for 30 minutes
at room temperature. The reaction was quenched by adding 40 mM cysteine solution in
deionized water to the peptide-SMCC-BSA solution to obtain a molar excess of cysteine
to peptide sample (approximately 7 nmoles cysteine/nmole of SMCC-BSA-peptide).

Table II. Putative NES in Human Topo IIα
(80-90)

-

G

L

Y

K

-

I

F

D

E

I

L

V

(230-241)

-

S

L

D

K

D

I

V

A

L

M

V

R

(467-476)

-

T

L

A

-

-

V

S

G

L

G

V

V

(569-580)

-

F

L

E

E

F

I

T

P

I

V

K

V

(1017-1028)

D

I

L

R

D

-

F

F

E

L

R

L

K

(1054-1065)

F

I

L

E

K

-

I

D

G

K

I

I

I
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The conjugates were purified by size exclusion chromatography at room
temperature using the Pharmacia P-500 FPLC system with LKB control Unit UV-1. The
high resolution column (10 mm inner diameter and 30 cm length) (Amersham Pharmacia,
Piscataway, NJ) was packed at 2.0 ml/min with Superdex 200 prep grade (Amersham
Pharmacia) in filtered and degassed PBS, pH 7.4. The peptide conjugates were loaded
onto the column using a 500 µl Superloop and were run at 0.5 ml/min in degassed dH2O.
The 500 µl fractions were collected with a Fraction-100 collector (Pharmacia Biotech)
and stored at 4°C overnight. Total protein was estimated in peak samples by measuring
the absorbance at 562 nm using the Fisherbrand Protein Assay. Approximately 25 µg of
protein from eluted fractions were loaded onto a 10% SDS-page gel and electrophoresed
with 7 watts for 2-3 h. Peptide conjugation was confirmed by silver stain analysis.
Similar fractions of crosslinked BSA-peptide were pooled and concentrated on a
Microsep 30k filter by centrifuging at 5,000 x g in an SS-34 rotor until dry. The samples
were eluted with 400 µl of PBS, pH 7.4 to obtain approximately 2 mg/ml peptideconjugate solution. FITC was solubilized in DMSO at 1 mg/ml and added to the peptide
sample in four 5 µl aliquots until a total of 20 µl of FITC (Sigma) were added. FITC was
reacted with the peptides for 6 h at 4°C, and then 23 µl of 1 M NH4Cl in PBS, pH 7.4
were added to the sample and incubated for 2 h at 4°C. FITC-BSA-peptide conjugates
were separated from unincorporated label by FPLC as described above. The samples
were concentrated in a SpeedVac and the ratio of fluorescein to protein was determined
by measuring the absorbance at 495 nm and 280 nm. The nuclear control,
tetramethylrhodamine-bovine serum albumin (TRITC-BSA), was obtained from Sigma.
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Microinjection
Microinjections were performed by Jennifer Derderian. To promote cell
adherence, Fisherbrand glass coverslips were pretreated with 1N HCl for a minimum of
4h at 50°C and then rinsed extensively with deionized water. Coverslips were washed in
100% ethanol and dried between pieces of Whatman paper. Subconfluent HeLa cells
were plated onto the center of glass coverslips in NUNC brand petri dishes and incubated
at 37°C for 24-48 hours preceding microinjection. Prior to microinjection, cells were
gently rinsed with sterile PBS warmed to 37°C and replaced with Leibovitz’s L-15
Medium containing no phenol red.
The peptide samples from above were centrifuged at 13,000 x g for 30 min at
4°C, and the supernatant then loaded into Eppendorf Femptotips (diameter of 0.5 µm ±
0.2 µm). All cells were injected using the semi-automated Eppendorf Injectman NI2 and
Femtojet microinjector on a Nikon TE 2000 inverted microscope under exactly the same
conditions (injection pressure (Pi), 100 hPa; compensation pressure (Pc), 30 hPa; injection
time (It) 0.2 sec, atmospheric conditions). Following injection, the cells were incubated at
37°C for up to 90 min, washed with Leibovitz’s L-15 Medium, and then fixed with 4%
paraformaldehyde for 3 minutes at room temperature, rinsed in PBS and mounted onto
Shandon microscope slides with mounting medium containing DAPI. Fluorescence was
observed with a Leitz Orthoplan 2 microscope and images were captured using a CCD
camera with Smart Capture program (Vysis, Downers Grove, IL).
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Topoisomerase IIα Cloning and Site Directed Mutagenesis
Topoisomerase IIα primers were designed that contained the eight amino acid
FLAG peptide preceded by a start codon and a Kozak motif (5’-ATG GAC TAC AAA
GAC GAT GAC GAC AAG GAA GTG TCA CCA TTG CAG CCT GTA AAT GAA
AAT ATG-3’ forward primer, 5’-ATG CGG CCG CTT AAA ACA GAT CAT CTT
CAT CTG ACT CTT C-3’ reverse primer). Amplification was performed with an
enzyme mixture of Taq and Pyrococcus species GB-D thermostable DNA polymerases
(Elongase, Invitrogen), in 60 mM Tris-SO4 (pH 9.1), 18 mM (NH4)2SO4, 2 mM MgSO4,
200 µM dNTP mixture and 200 nM each primer. Forty cycles were performed (94°C for
30s, 60°C for 30s, and 5.5 min at 68°C), and the PCR products were agarose gel-purified
and ligated to a pcDNA3.1 vector (CMV promoter) using a TOPO-TA cloning system
(Invitrogen). The 5’ end of the new FLAG-topo IIα fusion protein vector was sequenced
to ensure that the DNA was in-frame. Site-directed mutagenesis was performed using a
Quickchange XL site-directed mutagenesis kit (Stratagene). Briefly, 100 ng of template
dsDNA were mixed with 125 ng of each oligonucleotide primer, 2.5 units of PfuTurbo
DNA polymerase, in a reaction mixture containing 2 mM dNTPs. Eighteen cycles were
performed (95°C for 50 s, 60°C for 50 s, and 68°C for 20 min), after which the parental
plasmid was digested with methylation specific enzyme Dpn-I. Ultra-competent cells
were transformed with mutated plasmid and clones were sequenced to determine the
presence of desired mutations. DNA sequencing was performed at the H. Lee Moffitt
Cancer Center Molecular Biology Core Facility. Primers containing mutant sequences
are listed in Table III.
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Transfection Protocol
Human myeloma H929 and HL-60 cells (ATCC) were plated at log phase
density (2x105 cells/ml) two days prior to transfection. Transfection was performed as
previously described (Van den Hoff, et al., 1992). Briefly, 40 µg of wild-type or mutated
topoisomerase IIα plasmid in 300 µl of a solution containing 10 mM Tris-HCl, 1 mM
EDTA, pH 8.0, were precipitated by the addition of 30 µl of 5 M NaCl and two volumes
of 95% ethanol on ice for ten minutes. Plasmid was pelleted by centrifugation for fifteen
minutes at 20,000 x g at 4°C, washed with 75% ethanol and re-centrifuged. All
remaining ethanol was removed by pipet and the DNA immediately resuspended in 50 µl
of cytomix buffer containing 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4,
25 mM Hepes, 2 mM EGTA, 5 mM MgCl2, 2 mM ATP, and 5 mM glutathione, pH
adjusted to 7.6 by the addition of KOH. ATP and glutathione were made fresh and added
prior to each transfection (Van den Hoff et al., 1992). Two days prior to transfection,
human myeloma H929 cells and leukemia HL-60 cells were placed in fresh growth media
(RPMI/10% FBS/pen-strep) at a concentration of 2 x105 cells/ml. Cells were collected
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and 1.6x107 cells pelleted by centrifugation at 1500 x g for 5 minutes. Cell pellets were
washed twice in 10 ml of sterile PBS, resuspended in 350 µl of cytomix buffer (4°C),
mixed with prepared DNA and placed in a 4 mm electroporation cuvette. Electroporation
was at 250V/750 capacitance, after which cells were split into even groups and plated at
log (2 x105 cells/ml) and plateau (2 x106 cells/ml) growth conditions for twenty hours in
a 5 % CO2 incubator at 37°C with RPMI medium containing 5% FBS.

Immunofluorescence
Twenty hours post-transfection, viable H929 and HL-60 cells were isolated by
centrifugation at 2000 x g for 20 minutes at 20°C on a ficoll gradient and washed with
PBS. Transfected cells were plated on a glass microscope slide using cytospin funnels
and fixed with 4% paraformaldehyde at 20oC for ten minutes. The fixation was stopped
by washing in PBS and cells were permeabilized for twenty-four hours in a solution
containing 1% glycine and 0.25% Triton X-100 in PBS. Slides were stained with antiFLAG M2 monoclonal antibody-FITC conjugate (Sigma) diluted 1:100 with 0.1% NP-40
and 1% BSA in PBS, and incubated one hour at room temperature. Slides were washed
in PBS, dried briefly and counterstained with Vectashield mounting media antifade/DAPI
(1:1) (Vector Laboratories Inc., Burlingame, CA). Immunofluorescence was observed
with a Leitz Orthoplan 2 fluorescent microscope and images were captured by a CCDcamera with Smart Capture program (Vysis, Downers Grove, IL Quantitation of FITC
fluorescence was performed using the Adobe Photoshop 7.0 program.
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Western Blot
HeLa cells grown in RPMI media containing 5 % FBS were transfected
directly on 100 cm2 tissue culture plates. Plasmid DNA (10 µg) was mixed with 60 µl of
Superfect transfection reagent (Qiagen) in 300 µl of serum-free media for 10 minutes,
followed by 600 µl of serum containing media, and the entire mixture was then added
directly to cell culture plates. Transfection was allowed to proceed for three hours at
37°C in a 5 % CO2 incubator, and terminated by the removal of transfection solution and
the addition of 15 ml of 5% FBS containing RPMI media. After incubation for twentyfour hours, the cells were harvested by the addition of 0.53 mM EDTA, washed with cold
PBS, and lysed in SDS buffer (2% SDS, 10% glycerol, 0.06 M Tris, pH 6.8). Protein
from 2x105 cells per lane was separated on an 8% SDS-PAGE gels and electroblotted
(Biorad) onto nitrocellulose membranes (Amersham). The blots were blocked for one
hour at ambient temperature in a blocking buffer containing 0.1 M Tris-HCl buffered
saline, 0.5% tween-20, and 5% non-fat milk. Blots were stained by the direct addition of
anti-FLAG M2 (Sigma) antibody and incubated overnight at 4ºC. Membranes were
washed three times for ten minutes with 0.1 M Tris-HCl buffered saline and incubated
with anti-mouse IgG antibody (Sigma) in 0.1 M Tris-HCl buffered saline, 0.5% tween20, and 5% non-fat milk for sixty minutes at room temperature. Antibody binding was
visualized by ECL (Amersham) on autoradiography film (Kodak).
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RESULTS
Peptides NES1054-1066 and NES1017-1028 Signal the Nuclear Export of BSA-FITC
Of the six putative NES identified in topoisomerase IIα, two peptides, NES10541066

and NES1017-1028, signaled the export of BSA into the cytoplasm when microinjected

into the nuclei of HeLa cells (Figure 4). BSA-NES1054-1066 showed strong cytoplasmic
staining and was seen in the cytoplasm within 15 minutes of microinjection, as compared
to TRITC-BSA alone (not shown), or the mutated BSA-NES1054-1066 conjugate. BSANES1017-1028 also appeared cytoplasmic within 15 minutes of being microinjected into the
nucleus, but complete nuclear clearing (seen with BSA-NES1054-1066) was not observed
even after 90 minutes. The mutated BSA-NES1017-1028 was nuclear in all cells even 90
minutes after microinjection. BSA-NES80-90 (Figure 4), mutated BSA-NES80-90 (Figure 4),
BSA-NES230-241, mutated BSA-NES230-241, and BSA-NES467-476, BSA-NES569-580, and
mutated BSA-NES569-580 all remained in the nucleus even 4 h after microinjection (data
not shown).

LMB Blocks NES1054-1066 and NES1017-1028 Mediated Nuclear Export
LMB (Hamamoto, et al., 1983a; Hamamoto, et al., 1983b; Hamamoto, et al.,
1985) is a specific inhibitor of CRM-1 mediated nuclear export of proteins (Nishi, et al.,
1994). To determine if the nuclear export of BSA conjugated to peptides NES1054-1066
and NES1017-1028 was CRM-1 dependent, LMB pretreated HeLa cells were microinjected
in the presence of 2 ng/ml LMB in ethanol. Fluorescence microscopy demonstrated that
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Native

Mutated
NES1054-66

NES1017-28

NES80-91

LMB - NES 1017-28

LMB – NES1054-66

Figure 4: HeLa cells microinjected with either wild-type (left column) or mutated (right
column) peptide-BSA-FITC conjugates (green), and then counterstained with DAPI
(blue). A total of 20-50 cells were successfully microinjected per peptide and similar
results were seen in all cells. The bottom of the figure presents HeLa cells that were
microinjected with wild-type peptide-BSA-FITC conjugates in the presence of 2 ng/ml
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LMB. Mutated peptide BSA-NES 1054-66 is at a higher magnification than the other
micrographs.

LMB blocked the export of BSA conjugated to peptides NES1054-1066 and NES1017-1028
(Figure 4). BSA-NES1054-1066 had a strong perinuclear staining, suggesting that the
protein cargo is docking at the NPC (Siomi, et al., 1997; Arlucea, et al., 1998). Although
the NES defined by microinjection are sufficient to transport a non-shuttled protein to the
cytoplasm, these leucine rich sequences may or may not serve a role in exporting
topoisomerase IIα. To determine if these NES are necessary for topoisomerase IIα
export, I observed the trafficking of FLAG-topo IIα expressed in human myeloma cell
lines in the accelerated-plateau cell system.

Topoisomerase IIα Cloning, Site Directed Mutagenesis, and Gene Expression
I first attempted to study full-length topoisomerase IIα protein trafficking using a
green fluorescent protein-topoisomerase II alpha (GFP-topo IIα) fusion protein
expression vector. However, expression of GFP-topo IIα recombinant protein was found
to be cytotoxic, inducing apoptosis in all cell lines tested (HeLa, HL-60, H992, 8226,
MCF-7, Chinese hamster ovary) 16-48 hours after transfection. The GFP also inhibited
translocation of the wildtype topoisomerase-GFP fusion protein from the nucleus to the
cytoplasm in plateau density cells (data not shown). Additionally, a GFP-topo IIα fusion
plasmid in which the active-site tyrosine 805 was mutated to an alanine, GFP-topo IIα
A805, also produced similar negative results, being lethal to the transfected cells and
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minimally exported to the cytoplasm in plateau density cells, (again contrary to
endogenous topoisomerase IIα).
A final GFP plasmid was produced with a destabilized GFP-topo IIα fusion
protein, theorizing that the lethality of the fusion protein may be due to accumulation of
GFP-topo IIα in the transfected cells. Destabilized GFP fusion protein is turned over
every four hours in transfected cells, thus not allowing cellular accumulation of
recombinant protein to cytolytic levels. The destabilized GFP-topo IIα protein was also
cytotoxic and did not translocate to the cytoplasm in plateau density cells.
The lack of success with GFP fusion proteins led to an investigation into
alternative topoisomerase IIα fusion proteins, such as the FLAG peptide. FLAG peptide
is an eight amino acid protein (NYKNNNNK) that does not occur in nature. FLAG does
not contain any putative nuclear export signals and its small size limits any secondary
protein structure problems. HeLa cells transfected with FLAG-topo IIα plasmid vectors
express full-length (170 kDa) topoisomerase IIα recombinant proteins (Figure 5).
Human myeloma cells are comparatively small and very difficult to transfect with
plasmid DNA. In an attempt to transfect human myeloma cell lines, a number of
commercially available transfection reagents and numerous protocols were tried with no
success. The only technique that yielded positive transfectants was a method described
by Van den Hoff, et al., 1992. This method utilizes a cytomix buffer made to
approximate the intracellular environment (see Methods). In addition, this buffer
contains ATP and glutathione to promote the rapid repair of cellular membranes. I was
able to transfect myeloma cells with a high degree of efficiency for these cell lines (2-20
%) using the Van den Hoff cytomix buffer.
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A

B

C

D
207 kDa
117 kDa

Figure 5: Western blot of full-length FLAG-topo IIα protein. HeLa cells were
transfected with plasmid containing FLAG-topo IIα plasmid via cationic lipid, and
harvested after twenty hours. Protein extracts from 2x105 cells per lane were separated
on a SDS-PAGE gel, blotted onto nitrocellulose and probed with FLAG M2 antibody.
Lane A is protein from cells transfected with non-mutated FLAG-topo IIα plasmid, lane
B is FLAG-topo IIα plasmid 1054-1066, lane C transfected with FLAG-topo IIα plasmid
1017-1028, and lane D is a non-transfected control.cells were transfected with FLAGtopo IIα expression vectors possessing mutated hydrophobic residues in the nuclear
export sites at 1017-1028 and 1054-1066 (Table III).
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FLAG-topo IIα Immunofluorescence
BSA-peptide microinjection data indicated that the putative nuclear export sites at
1017-1028 and 1054-1066 may function to signal export of topoisomerase IIα. To
confirm these data with a full-length topoisomerase IIα protein, H929 human myeloma
Twenty hours post-transfection, viable cells were isolated by centrifugation on a Ficollpaque gradient and plated on glass microscope slides using cytospin funnels. After fixing
and permeabilization, slides were stained with anti-FLAG M2 monoclonal antibodyFITC conjugate and counterstained with mounting media containing DAPI to show the
location of the nuclei. Images were acquired using a fluorescent microscope (Figure 6),
with quantitation of FITC fluorescence using Adobe Photoshop 7.0 (data expressed in
Figure 7). Figures 6 and 7 establish that the wild-type (non-mutated) FLAG-topo IIα
protein is present in the nucleus of the cells plated at log density, whereas FLAG-topo IIα
protein is located in the cytoplasm in cells plated at plateau density.
Quantitation of fluorescence revealed a statistically significant shift (p=0.00001)
for log cells with a nuclear:cytoplasmic ratio of 5.9:1, to a ratio of 0.42:1 in plateau cells
(Figure 6) when using the wild-type FLAG-topo IIα plasmid. When the putative export
signals at either 1017-1028 (Figure 7) or 1054-1066 were mutated, export to the
cytoplasm was abrogated. Quantitative analysis of fluorescence of both mutant proteins
(1017-1028 or 1054-1066) revealed no statistically significant change in the levels of
nuclear or cytoplasmic FLAG-topo IIα in log or plateau density cell cultures. Even
though export to the cytoplasm of mutant 1054-1066 was abrogated, qualitatively it
appeared that the mutated FLAG-topo IIα protein was localized predominantly at the
nuclear membrane as compared to mutant 1017-1028. The putative signal at 467-476

30

was similar to wild-type (Figure 7) as were putative signals at amino acid 80-91, 230241, and 569-580 (data not shown).

1053-1066 plateau

Nuclear
Cytoplasmic

1053-1066 log

1016-1027 plateau

1016-1027 log

Wild-type plateau

*p=0.00001

100

75

50

25

0

Wild-type log

FLAG-Topo II alpha protein
(% nuclear vs cytoplasmic)
Figure 6: Nuclear export of wild-type and mutant FLAG-topo IIα plasmids. Human
myeloma H929 transfected cells (n=20) stained with anti-FLAG M2 monoclonal
antibody-FITC conjugate were assayed for nuclear and cytoplasmic immunofluorescence.
Quantitation of FITC fluorescence was performed using Adobe Photoshop 7.0 program.
Wild-type FLAG-topo IIα was exported to the cytoplasm in cells at plateau density
(p=0.00001), whereas topoisomerase IIα mutated at the putative export sites, 1016-1027
and 1053-1066, did not demonstrate statistically significant levels of export to the
cytoplasm.
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Log
FITC

DAPI

Plateau
Merged

FITC

DAPI

Merged

Wild-type

Mutated
NES 467-77

Mutated
NES 1017-28

Mutated
NES 1054-66

Figure 7: FLAG-topo IIα Immunofluorescence. Human multiple myeloma H929 cells
were transfected by electroporation with full-length wild-type and mutated topo IIα, and
plated for twenty hours at log and plateau cell densities. Cytospins containing fixed cells
were stained with FITC labeled anti-FLAG M2 antibody (green), counterstained with
DAPI for nuclear staining, and assayed by immunofluorescent microscopy.
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Peptide NES1054-1066 and NES1017-1028 are Conserved
To determine if peptides NES1054-1066 and NES1017-1028 are conserved, a BLAST
search of the SWISS PROT database was performed to identify homologous sequences in
topoisomerase IIα. Tables IV and V summarize a list of representative species
containing homologous topoisomerase IIα sequences. The data show that the
characteristic spacing of hydrophobic residues in peptides NES1054-1066 and NES1017-1028
are highly conserved in a broad range of species. For example, leucine residues
appearing in human topoisomerase IIα NES are often substituted with the hydrophobic
amino acids isoleucine or valine. Furthermore, Phe1054 and Ile1055 in peptide NES1054-1066
are highly conserved from mammals to the most primitive eukaryotic organism, Giardia
lamblia, unlike Leu1056. This suggests that the presence of phenylalanine and isoleucine
are critical for nuclear export of this peptide, and thus an omission of these two
hydrophobic amino acids from the peptide sequence could explain why a previous report
failed to identify NES1054-1066 as a nuclear export signal (Mirski, et al., 2003).

NES1054-1066 and NES1017-1028 Reside Within a Putative Coiled-coil Domain
Predicting the structural features of the region containing NES1017-1028 and
NES1054-1066 was of particular interest. Each topoisomerase II monomer can be divided
into three domains, 1) an N-terminal domain that contains the ATP-binding region, 2) the
central domain containing the active site tyrosine residue, and 3) the C-terminal domain
that contains the nuclear localization sequences (Figure 1) (Watt and Hickson, 1994).
Both of the NES are situated upstream of the bipartite NLS (Figure 8) and downstream of
the active-site tyrosine residue (Tyr805). Furthermore, several CK-2 phosphorylation
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Table IV. Sequence Alignment of Topo IIα NES1017-1028
Homo sapiens (human) NES1017-1028

D

I

L

R

D

F

F

E

L

R

L

K

Sus scrofa (pig), Mus musculus (mouse),
Rattus norvegicus (rat)

D

I

L

R

D

F

F

E

L

R

L

K

Cricetulus griseus (Chinese hamster)

D

I

L

*

D

F

F

E

L

R

L

K

Gallus gallus (chicken)

D

I

L

*

*

F

F

E

L

R

L

*

Saccharomyces cerevisiae (yeast)

*

I

L

*

*

F

*

*

V

R

L

*

Aspergillus niger (fungi), penicillium
citrinum (fungi)

D

I

L

*

*

F

F

*

V

R

L

K

Nicotiana tabacum (tobacco plant)

D

I

L

*

*

F

*

*

V

R

L

*

Encephalitozoon cuniculi (protozoa)

*

I

L

*

*

F

*

*

V

R

L

*

Bombyx mori (silkmoth)

*

I

L

R

*

F

*

*

L

R

V

*

sites downstream of both NES have been identified in vitro and could be important for
regulating the subcellular localization of topoisomerase IIα. Although NES1017-1028 alone
is predicted to form an α-helix (Mirski, et al., 2003), I was interested in predicting the
motif of the complete amino acid sequence stretching from NES1017-1028 to NES1054-1066.
According to EMBOSS and Predict Protein, two programs designed to predict protein
motifs, amino acids 1017-1066 are characterized by a high potential to form α -helices
and also contain five 4-3 hydrophobic repeats, a typical feature of a coiled-coil motif.
Such a repeating pattern of hydrophobic amino acids has been shown to form a
hydrophobic core, which is critical for dimerization (Sodek, et al., 1972). In this manner,
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Table V. Sequence Alignment of DNA Topo IIα NES1054-1066
Homo sapiens (human) NES1054-1066

F

I

L

E

K I

D G K I

I

I

E

F

I

L

E

K I

D G K I

I

I

E

F

I

L

E

K I

D G K I

V I

E

Caenorhabditis elegans (nematode)

F

I

L

*

K I

*

*

*

I

V L

E

Saccharomyces cerevisiae (yeast)

F

I

*

*

*

I

*

*

*

L

*

V *

Candida glabrata (yeast)

F

I

*

*

*

I

*

*

*

L

I

V *

Aspergillus candidus (fungi),
Trichophyton rubrum (fungi)

F

V *

*

*

I

*

G *

L

V V *

Giardia lamblia (protist)

F

I

*

*

*

I

*

*

L

*

Cricetulus griseus (Chinese hamster),
Sus scrofa (pig)
Gallus gallus (chicken), Mus musculus
(mouse), Rattus norvegicus (rat)

*

I

*

the hydrophobic amino acids are predicted to align on the same interface that facilitates
DNA binding or protein-protein interactions. Interestingly, amino acids 1013-1056 in
topoisomerase IIα have previously been shown to form a stable two-stranded α-helical
coiled-coil in solution (Frere, et al., 1995; Frere-Gallois, et al., 1997; Bjergbeck, et al.,
1999). Perhaps more importantly than the predictive data above, the crystal structure of
topoisomerase II from S. cervisiae was shown to have primary and secondary
dimerization domains (Fass, et al., 1999). The primary dimerization region is highly
conserved and corresponds to amino acids 1013-1056 in human topoisomerase IIα
(Frere, et al., 1995).
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DISCUSSION
Topoisomerase IIα is an essential enzyme involved in the normal processing of
DNA and is expressed at high levels in rapidly dividing cells. These qualities make it a
perfect target for chemotherapeutic agents in treatment of various cancers.
Human topoisomerase I (Mo, et al., 2000), IIα and IIβ (Mirski, et al., 1999) have
NLS that target their movement into the nucleus, but only one report has begun to address
the mechanism of nuclear export of topoisomerase IIα and topoisomerase IIβ (Mirski, et
al., 2003). The nuclear export of topoisomerase I in response to topotecan or
camptothecin exposure has been reported (Danks, et al., 1996), as has the redistribution
of topoisomerase I from the nucleus to the nucleoli (Buckwalter, et al., 1996). The lack
of data describing the nuclear-cytoplasmic shuttling of topoisomerase enzymes may be
because topoisomerase is usually found to occur in the nucleus of cells, and a
cytoplasmic distribution of topoisomerase IIα has only been attributed to the expression
of a truncated protein that has lost its C-terminal NLS. However, proteins that appear
predominately nuclear may still shuttle between the nucleus and the cytoplasm, if the rate
of nuclear import is greater than the rate of nuclear export. Thus, demonstrating that a
protein shuttles between the nucleus and cytoplasm requires defining the specific
conditions that will shift the steady state kinetics toward nuclear export. Many conditions
have been shown to alter the shuttling of proteins between the nucleus and cytoplasm,
including changes in the cell cycle and oxidative stress (reviewed in Damelin, et al.,
2002). For example, in the accelerated-plateau cell model (Valkov, et al., 2000; Engel, et
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al., 2004) used in the present experiments, it is likely that intensive cell-cell contact
initiates a signal that induces the export of topoisomerase IIα to the cytoplasm (Nix and
Beckerle, 1997; Gottardi, et al., 1996). This is supported by the findings of others that a
cytoplasmic distribution of topoisomerase IIα occurs in the outer-proliferating cells of
multi-cell spheroids in Xenograft tumors when compared to monolayers formed by these
cells (Oloumi, et al., 2000). Phosphorylation has also been shown to be important in
regulating the subcellular localization of many proteins and could have a role in
topoisomerase IIα trafficking. This is suggested by the finding that the cells of multi-cell
spheroids contain a cytoplasmic pool of topoisomerase IIα and have a 10-fold decrease in
the phosphorylation state of the enzyme when compared to monolayers (Oloumi, et al.,
2000). Since CK-2 has been shown to phosphorylate topoisomerase IIα on several serine
and threonine residues near the NES or NLS (Ackerman, et al., 1985), CK-2 is a logical
candidate to investigate for modulating topoisomerase IIα trafficking.
One of the potential consequences of exporting a pool of topoisomerase IIα to the
cytoplasm is a decrease in sensitivity to topoisomerase poisons. This could result from
cytoplasmic topoisomerase IIα serving as a drug sink, by trapping VP-16 in this
compartment (Ernst, et al., 2000). This is supported by data demonstrating that the
binding of VP-16 to topoisomerase IIα can occur in the absence of DNA (Burden, et al.,
For this to occur, the amount of drug binding to topoisomerase IIα would need to be
sufficient to result in a decrease in drug-induced DNA damage (Burden, et al., 1996).
Another possibility is that the shuttling of topoisomerase IIα to the cytoplasm results in a
decrease in the amount of nuclear enzyme available to form enzyme-drug-DNA ternary
complexes. In either case, blocking the export of topoisomerase IIα with drugs such as
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1 MEVSPLQPVN ENMQVNKIKK NEDAKKRLSV ERIYQKKTQL EHILLRPDTY IGSVELVTQQ
61 MWVYDEDVGI NYREVTFVPG LYKIFDEILV NAADNKQRDP KMSCIRVTID PENNLISIWN
121 NGKGIPVVEH KVEKMYVPAL IFGQLLTSSN YDDDEKKVTG GRNGYGAKLC NIFSTKFTVE
181 TASREYKKMF KQTWMDNMGR AGEMELKPFN GEDYTCITFQ PDLSKFKMQS LDKDIVALMV
241 RRAYDIAGST KDVKVFLNGN KLPVKGFRSY VDMYLKDKLD ETGNSLKVIH EQVNHRWEVC
301 LTMSEKGFQQ ISFVNSIATS KGGRHVDYVA DQIVTKLVDV VKKKNKGGVA VKAHQVKNHM
361 WIFVNALIEN PTFDSQTKEN MTLQPKSFGS TCQLSEKFIK AAIGCGIVES ILNWVKFKAQ
421 VQLNKKCSAV KHNRIKGIPK LDDANDAGGR NSTECTLILT EGDSAKTLAV SGLGVVGRDK
481 YGVFPLRGKI LNVREASHKQ IMENAEINNI IKIVGLQYKK NYEDEDSLKT LRYGKIMIMT
541 DQDQDGSHIK GLLINFIHHN WPSLLRHRFL EEFITPIVKV SKNKQEMAFY SLPEFEEWKS
601 STPNHKKWKV KYYKGLGTST SKEAKEYFAD MKRHRIQFKY SGPEDDAAIS LAFSKKQIDD
661 RKEWLTNFME DRRQRKLLGL PEDYLYGQTT TYLTYNDFIN KELILFSNSD NERSIPSMVD
721 GLKPGQRKVL FTCFKRNDKR EVKVAQLAGS VAEMSSYHHG EMSLMMTIIN LAQNFVGSNN
781 LNLLQPIGQF GTRLHGGKDS ASPRYIFTML SSLARLLFPP KDDHTLKFLY DDNQRVEPEW
841 YIPIIPMVLI NGAEGIGTGW SCKIPNFDVR EIVNNIRRLM DGEEPLPMLP SYKNFKGTIE
901 ELAPNQYVIS GEVAILNSTT IEISELPVRT WTQTYKEQVL EPMLNGTEKT PPLITDYREY
961 HTDTTVKFVV KMTEEKLAEA ERVGLHKVFK LQTSLTCNSM VLFDHVGCLK KYDTVLDILR
1021 DFFELRLKYY GLRKEWLLGM LGAESAKLNN QARFILEKID GKIIIENKPK KELIKVLIQR
1081 GYDSDPVKAW KEAQQKVPDE EENEESDNEK ETEKSDSVTD SGPTFNYLLD MPLWYLTKEK
1141 KDELCRLRNE KEQELDTLKR KSPSDLWKED LATFIEELEA VEAKEKQDEQ VGLPGKGGKA
1201 KGKKTQMAEV LPSPRGQRVI PRITIEMKAE AEKKNKKKIK NENTEGSPQE DGVELEGLKQ
1261 RLEKKQKREP GTKTKKQTTL AFKPIKKGKK RNPWSDSESD RSSDESNFDV PPRETEPRRA
1321 ATKTKFTMDL DSDEDFSDFD EKTDDEDFVP SDASPPKTKT SPKLSNKELK PQKSVVSDLE
1381 ADDVKGSVPL SSSPPATHFP DETEITNPVP KKNVTVKKTA AKSQSSTSTT GAKKRAAPKG
1441 TKRDPALNSG VSQKPDPAKT KNRRKRKPST SDDSDSNFEK IVSKAVTSKK SKGESDDFHM
1501 DFDSAVAPRA KSVRAKKPIK YLEESDEDDL F

Figure 8: The complete amino acid sequence of human DNA topoisomerase
IIα (accession number NP 001058). The active-site tyrosine residue (805) is indicated
( ): NES1017-1028, C1017DILRDFFELRLK1028 and NES1054-1066, C1054FILEKIDGKIIIE1066
are shaded; bipartite NLS is single underlined; ser/thr CK2 phosphorylation sites are
italicized; the predicted coiled-coil region is outlined with a box.1996).
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LMB may sensitize cells to topoisomerase poisons by maintaining the amount of drug
target in the nucleus. Although LMB has been shown to have undesirable cytotoxic
effect in clinical trials, synthetic derivatives of LMB have become available and may be
promising alternatives to LMB therapy (Kalesse, et al., 2001; Koster, et al., 2003) in
hematological malignancies.
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FUTURE DIRECTIONS
Crm1 Proof of Principle
In this paper I relied primarily on the Crm1 inhibitory activity of LMB to prove
that topoisomerase export is Crm1 mediated, however I was unable to show that blocking
export would make cancer cells more sensitive to etoposide or mitoxantrone
chemotherapy because LMB itself is so toxic. It may be possible to block Crm1 mediated
export by other more specific means. One way in which this could be done is by using an
antisense phosphorothioate oligonucleotide or siRNA specifically directed against Crm1.
This might work to inhibit expression of Crm1 without the cytotoxic effects of LMB.
Once Crm1 expression is knocked out, or at least substantially reduced, it may be
possible to investigate an increased sensitivity to topoisomerase IIα directed
chemotherapy (i.e., etoposide and mitoxantrone).
It is interesting to note that the dimerization region of topoisomerase IIα contains
both NES amino acid sequences. As a proof of principle experiment, a plasmid coding for
the dimerization region could be produced and transfected into cells. If it is determined
that nuclear export of topoisomerase IIα is blocked, I could then proceed to determine
whether the cells are more sensitive to chemotherapy. It is unknown whether this peptide
would block all nuclear export or only export of topoisomerase IIα. Specificity could be
determined is by using a plasmid containing a GFP/MAPKK NES fusion as a control for
the specificity of export blocking (Kanwal, et al., 2002). If a recombinant protein
possessing the dimerization region was effective, peptidomimetics could be produced,
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and possibly small molecules developed based on the peptide binding properties that
could block nuclear export.
High-Throughput Assay
New compounds are being developed to block nuclear export as a means to treat
cancer. Using multiple myeloma cell lines I can easily test inhibition of nuclear export
using the log vs. plateau system developed in this laboratory. Potential export blockers
could be tested in cell culture in both log and plateau cell density conditions.
Immunofluorescent staining for topoisomerase IIα could be performed, and pixel
intensities determined to give a relative measure of nuclear export.

Phosphorylation of Topoisomerase II alpha
Even though I have found the NES responsible for nuclear export, and that it is
Crm1 mediated, the exact mechanism that is inducing nuclear export of topoisomerase in
cancer cells has not yet been determined. A likely candidate is phosphorylation of the
topoisomerase molecule itself. Heretofore it has not been determined whether
phosphorylation is necessary for nuclear export of topoisomerase IIα. Caseine kinase II
has been shown to phosphorylate topoisomerase IIα on several serine and threonine
residues near the NES or NLS (Ackerman, et al., 1985), and therefore is a logical
candidate to investigate for modulating topoisomerase IIα trafficking. There are many
ways in which phosphorylation could induce nuclear export, phosphorylation may affect
topoisomerase dimerization, and it could reveal or mask nuclear localization or nuclear
export signals by changing the molecular conformation of topoisomerase IIα.
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If it is discovered that phosphorylation in necessary for nuclear export, there are a
number of phosphorylation inhibitors that I could test in the high-throughput assay.
Figure 1 maps out the potential phosphorylation sites on the topoisomerase IIα peptide.
Specific inhibitors of casein kinase 2, protein kinase C, p34cdc2, or MAP kinase could be
tested. In addition, as a proof of principle experiment, antisense phosphorothioate
oligonucleotides or siRNA directed at each kinase could be investigated to see if blocking
topoisomerase IIα phosphorylation negatively regulates nuclear export.

Other Questions
Another question that could be addressed in future experiments is whether
topoisomerase IIα is exported as a monomer or a dimer. It is possible that a
topoisomerase IIα monomer would likely reveal export signals for CRM-1 binding.
Dimerization and phosphorylation status may be interdependent of each other.
Also, it is very likely that nuclear export that is caused by plateau cell densities
may be mediated by a signaling pathway, microarray analysis may provide some clue as
to what pathway(s) may be involve. The signaling pathway may provide additional
targets for chemotherapy.
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SUMMARY
Resistance to chemotherapeutic drugs is a major obstacle in the treatment of
leukemia and myeloma. This lab has previously reported that resistance to topoisomerase
IIα poisons such as VP-16 was found to increase dramatically with concurrent increases
in cell density (Valkov, et al., 2000; Engel, et al., 2004). Myeloma and leukemic cells in
transition from low-density log phase conditions to high-density plateau phase conditions
exhibited a substantial export of endogenous topoisomerase IIα from the nucleus to the
cytoplasm. In order for topoisomerase-targeted chemotherapy to function, the
topoisomerase target must have access to the nuclear DNA. Thus, the nuclear export of
topoisomerase IIα must be added to the list of potential mechanisms of resistance to
topoisomerase poisons. It is unique in that it does not require drug exposure and may
mimic the high cell density microenvironment seen in the bone marrow of patients with
multiple myeloma. Further defining this mechanism, and possibly modulating export,
may lead to methods to preclude this avenue of resistance.
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